Literature DB >> 8841367

Surgical management and treatment of esophageal fistula.

H C Fernando1, J R Benfield.   

Abstract

Esophageal fistula may involve the respiratory or cardiovascular system. Fistulas involving the respiratory system which originate from esophageal cancers are the most common. Diagnosis is best made with barium esophagogram. ERF of any cause usually leads to repetitive contamination of the respiratory tract, resulting in sepsis and death of the patient if untreated. In the case of MERF, whether from esophageal or lung cancer, only palliative treatment is usually possible. Better results, including cure, may be expected when a MERF is caused by lymphoma. Curative operation with closure of the fistula is usually possible for BERF if the fistula is identified and treated before irreversible damage has been done by infection, sepsis, and malnutrition. Esophagocardiovascular fistulas occur infrequently in comparison with ERF. These may involve the aorta, usually as a result of a thoracic aneurysm. Rarely one may encounter esophageal fistula to the pericardium or heart. Few survivors have been reported, but successful management is possible if early diagnosis is made and prompt surgical management is undertaken.

Entities:  

Mesh:

Year:  1996        PMID: 8841367     DOI: 10.1016/s0039-6109(05)70501-6

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  3 in total

1.  Surgical treatment of aortobronchial and aortoesophageal fistulae due to thoracic aortic aneurysm.

Authors:  Ercan Eren; Cuneyt Keles; Mehmet Erdem Toker; Suat Ersahin; Vedat Erentug; Mustafa Guler; Gokhan Ipek; Esat Akinci; Mehmet Balkanay; Cevat Yakut
Journal:  Tex Heart Inst J       Date:  2005

2.  Successful tubes treatment of esophageal fistula.

Authors:  Ning Zhou; Wei-xing Chen; You-ming Li; Zhun Xiang; Ping Gao; Ying Fang
Journal:  J Zhejiang Univ Sci B       Date:  2007-10       Impact factor: 3.066

3.  Bronchoesophageal fistula in a patient with non-Hodgkin's lymphoma.

Authors:  V Valenti; D Martínez-Cecilia; P Priego; P Cohen; A Martínez-Isla
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.